…
Aquarius Surgical Technologies Inc., through its subsidiary, Surgical Lasers Inc., engages in the development, sale, distribution, and marketing of technologies for use in surgical and other environments in Canada and the United States. It offers integrated laser-based solutions across multiple medical disciplines, including urology, gynecology, ophthalmology, thoracic, ENT, cardiovascular, and neurosurgery. The company was incorporated in 1986 and is based in Toronto, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Aquarius Surgical Technologies Inc is a Canada-listed company with limited public disclosures about its operations and commercial products; publicly available filings and corporate information are sparse. Long-term growth could be driven by successful clinical validation, regulatory approvals, commercialization and partnerships common to surgical-technology firms, and investors may find exposure to potential medical-device upside while monitoring milestone progress.
Key risks include early-stage operations with uncertain or no revenue, regulatory and clinical execution risk, dependency on successful financing which could be dilutive, and limited transparency that makes assessment of competitive position difficult.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Income before tax | -1.17M | -0.75M | -0.72M | -0.86M | -1.81M |
| Net income | -1.17M | -0.76M | -0.72M | -0.86M | -1.81M |
| Selling general administrative | 0.56M | 0.59M | 0.73M | 0.77M | 0.87M |
| Gross profit | 0.05M | 0.13M | 0.08M | 0.13M | 0.22M |
| Reconciled depreciation | 0.03M | 0.03M | 0.01M | 0.05M | 0.14M |
| Ebit | - | - | -0.65M | -0.69M | -0.79M |
| Ebitda | - | - | -0.52M | -0.61M | -0.66M |
| Operating income | -0.86M | -0.75M | -0.75M | -0.69M | -0.79M |
| Interest expense | 0.31M | 0.29M | 0.20M | 0.20M | 0.22M |
| Tax provision | 0.00M | 0.01M | 0.00M | - | - |
| Interest income | 0.30M | 0.00M | 0.03M | 0.01M | 0.01M |
| Net interest income | -0.32M | -0.26M | -0.21M | -0.20M | 0.01M |
| Total revenue | 0.09M | 0.21M | 0.20M | 0.33M | 0.58M |
| Total operating expenses | 0.64M | 0.69M | 0.86M | 1.02M | 1.38M |
| Cost of revenue | 0.04M | 0.07M | 0.12M | 0.20M | 0.37M |
| Total other income expense net | -0.30M | 0.00M | 0.14M | 0.03M | -1.03M |
| Net income from continuing ops | -1.17M | -0.76M | -0.72M | -0.86M | -1.81M |
| Net income applicable to common shares | -1.17M | -0.76M | -0.72M | -0.86M | -1.81M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Total assets | 1.95M | 0.57M | 0.68M | 0.89M | 0.95M |
| Other current assets | - | - | - | 0.00M | - |
| Total liab | 7.72M | 5.18M | 4.53M | 4.11M | 3.34M |
| Total stockholder equity | -5.77M | -4.61M | -3.85M | -3.21M | -2.39M |
| Common stock | - | 19.95M | 19.95M | 19.87M | 19.84M |
| Capital stock | 19.95M | 19.95M | 19.95M | 19.87M | 19.84M |
| Retained earnings | -35.04M | -33.87M | -33.12M | -32.39M | -31.53M |
| Other assets | - | - | - | - | -0.00M |
| Cash | 0.01M | 0.11M | 0.12M | 0.16M | 0.15M |
| Total current liabilities | 1.74M | 1.87M | 1.51M | 1.65M | 1.00M |
| Net debt | 6.41M | 3.85M | 3.28M | 3.08M | 0.66M |
| Short term debt | - | 0.33M | 0.19M | 0.16M | 0.15M |
| Short long term debt | 0.46M | 0.71M | 0.47M | 0.78M | 0.58M |
| Short long term debt total | - | - | - | - | 2.50M |
| Property plant equipment | - | 0.08M | 0.10M | 0.01M | 0.30M |
| Total current assets | 0.10M | 0.19M | 0.27M | 0.61M | 0.64M |
| Long term investments | 1.80M | 0.30M | 0.30M | 0.28M | 0.00M |
| Net tangible assets | - | - | -3.85M | -3.21M | -2.39M |
| Net receivables | 0.05M | 0.05M | 0.08M | 0.09M | 0.20M |
| Long term debt | 5.96M | 3.25M | 2.93M | 2.46M | 0.23M |
| Inventory | 0.02M | 0.02M | 0.04M | 0.04M | 0.02M |
| Accounts payable | 1.25M | 1.14M | 1.02M | 0.87M | 0.41M |
| Non current assets total | 1.85M | 0.38M | 0.41M | 0.29M | 0.30M |
| Capital lease obligations | 0.05M | 0.08M | 0.11M | 0.00M | - |
| Long term debt total | - | 3.31M | 3.01M | 2.46M | 2.35M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Investments | -1.80M | -0.00M | -0.00M | -0.01M | -0.10M |
| Change to liabilities | - | - | 0.35M | 0.45M | 0.09M |
| Total cashflows from investing activities | -1.80M | -0.00M | 0.00M | -0.01M | -0.10M |
| Net borrowings | -0.17M | -0.09M | -0.09M | 0.15M | 0.68M |
| Total cash from financing activities | 2.08M | 0.24M | -0.11M | 0.13M | 0.59M |
| Change to operating activities | - | - | 0.33M | -0.04M | 0.01M |
| Net income | -1.17M | -0.76M | -0.72M | -0.86M | -1.81M |
| Change in cash | -0.10M | -0.01M | -0.04M | 0.01M | 0.04M |
| Begin period cash flow | 0.11M | 0.12M | 0.16M | 0.15M | 0.11M |
| End period cash flow | 0.01M | 0.11M | 0.12M | 0.16M | 0.15M |
| Total cash from operating activities | -0.38M | -0.25M | 0.08M | -0.11M | -0.45M |
| Issuance of capital stock | - | - | - | - | 0.00M |
| Depreciation | 0.03M | 0.03M | 0.01M | 0.05M | 0.14M |
| Other cashflows from investing activities | -1.80M | - | - | - | 0.00M |
| Dividends paid | - | 0.00M | 0.00M | 0.00M | - |
| Change to inventory | -0.00M | 0.03M | 0.00M | -0.02M | 0.08M |
| Change to account receivables | -0.00M | 0.03M | 0.01M | 0.12M | -0.06M |
| Sale purchase of stock | - | - | - | 0.00M | -0.00M |
| Other cashflows from financing activities | - | -0.02M | -0.02M | -0.02M | -0.09M |
| Change to netincome | - | - | 0.11M | 0.19M | 1.10M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.01M | 0.10M |
| Change in working capital | 0.11M | 0.19M | 0.69M | 0.50M | 0.28M |
| Stock based compensation | - | 0.00M | 0.01M | 0.00M | 0.02M |
| Other non cash items | 0.30M | 0.29M | 0.23M | 0.22M | 0.31M |
| Free cash flow | -0.38M | -0.26M | 0.08M | -0.11M | -0.51M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ASTI Aquarius Surgical Technologies Inc |
- -% |
0.01 | - | - | 5.52 | 31.44 | 96.08 | 56.94 |
| BLO Cannabix Technologies Inc |
- -% |
0.40 | - | - | 556.83 | 57.80 | 564.68 | -11.28 |
Aquarius Surgical Technologies Inc., through its subsidiary, Surgical Lasers Inc., engages in the development, sale, distribution, and marketing of technologies for use in surgical and other environments in Canada and the United States. It offers integrated laser-based solutions across multiple medical disciplines, including urology, gynecology, ophthalmology, thoracic, ENT, cardiovascular, and neurosurgery. The company was incorporated in 1986 and is based in Toronto, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Lorne Stewart MacFarlane | CEO & CFO | NA |
| Mr. Brian Wagner | Vice President of Sales for SLI US Inc. | NA |
| Mr. Christopher H. Freeman | Secretary | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.